SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-QSB

              Quarterly Report Pursuant to Section 13 or 15(d) of
                      The Securities Exchange Act of 1934

                 For the quarterly period ended: March 31, 2000

                         PATHOBIOTEK DIAGNOSTICS, INC.
                         -----------------------------
             (Exact name of registrant as specified in its charter)


TEXAS                           0-28519                 76-0510754
--------                        -------                 ----------
(State or other                 (Commission             (IRS Employer
jurisdiction of                 File Number)            Identification No.)
Incorporation

7010 N.W. 100 Drive, Bldg A. Suite 101, Houston, TX  77092
----------------------------------------------------------
(Address of principal executive offices)        (Zip Code)


Registrant's telephone number, including area code:  (713) 785-4722

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  report(s),  and  (2) has  been  subject  to the  filing
requirements for at least the past 90 days.


                Yes  X                  No
                   -----                   -----

Number of outstanding  shares of the  registrant's  common stock as of March 31,
2000: 12,517,868 (not including 1,184,283 shares subscribed but not issued)

<PAGE>

ITEM 1. FINANCIAL INFORMATION

        Part I.  Financial Statements

<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
(Unaudited)

BALANCE SHEETS

                                                            March 31, 2000              December 31, 1999
                                                            --------------              -----------------
<S>                                                       <C>                           <C>
ASSETS

CURRENT ASSETS

    Cash and cash equivalents                             $         146,440             $    24,135
    Receivable from parent company                                   13,185                  13,185
    Employee receivables                                              2,158                   2,158
    Other receivables                                                     -                     270
                                                            ----------------            ------------
Total current assets                                                161,783                  39,748

PROPERTY AND EQUIPMENT, at cost                                     136,506                 131,361
    Less: Accumulated depreciation                                  (73,385)                (67,848)
                                                            ----------------            ------------
                                                                     63,121                  63,513

OTHER ASSETS
    Patent costs                                                     46,199                  44,699
    Less: Accumulated amortization                                   (6,598)                 (6,039)
    Other assets                                                        300                     300
                                                            ----------------            ------------
                                                                     39,901                  38,960

                                                            ----------------            ------------
                                                          $         264,805             $   142,221
                                                            ================            ============

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
    Payable to parent company                                             -             $         -
    Trade accounts payable and accrued expenses           $       1,321,964               1,166,412
    Current portion of long-term debt                                71,236                  87,290
                                                            ----------------            ------------
Total current liabilities                                         1,393,200               1,253,702

SHAREHOLDERS' EQUITY
    Common stock, $.001 par value,
      authorized 20,000,000 shares,
      issued and outstanding 12,517,868 shares                                                5,967
      stock subscribed but not issued 1,184,283 shares               13,702
      (Note 6)
    Additional paid in capital                                    1,517,095               1,248,394
    Deficit accumulated during the development stage             (2,659,192)             (2,370,418)
                                                            ----------------            ------------
Total shareholders' equity                                       (1,128,395)             (1,111,481)
                                                            ----------------            ------------
                                                          $         264,805             $   142,221
                                                            ================            ============

</TABLE>


See notes to financial statements.

<PAGE>
<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT
(Unaudited)



                                                            March 31, 2000              March 31, 1999
                                                           ---------------              --------------
<S>                                                      <C>                            <C>
Revenues                                                 $              0               $       0
Direct costs                                                            0                       0
                                                           ---------------              ----------
Gross profit                                                            0                       0

Administrative and general expenses                               281,491                       0
Depreciation expense                                                5,537                       0
                                                           ---------------              ----------
                                                                  287,028                       0

                                                           ---------------              ----------
Loss from operations                                             (287,028)                      0

Other income                                                            0                       0
Interest expense                                                   (1,746)                      0
                                                           ---------------              ----------
                                                                   (1,746)                      0
                                                           ---------------              ----------
Loss before income taxes                                         (288,774)                      0
Federal income taxes - current expense (benefit)                        0                       0
                                                           ---------------              ----------
Net loss                                                         (288,774)                      0

Accumulated deficit at beginning of period                     (2,370,418)                      0
                                                           ---------------              ----------
Deficit accumulated during the development stage         $     (2,659,192)              $       0
                                                           ===============              ==========

Weighted Average number of Shares                              12,517,868
Profit (loss) per share                                             ($.02)              $      .0

</TABLE>

See notes to financial statements.

<PAGE>
<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
(Unaudited)


                                                            March 31, 2000              March 31, 1999
                                                           ----------------             --------------
<S>                                                     <C>                             <C>

OPERATING ACTIVITIES
Net loss                                                $        (288,774)              $       0
Adjustments to reconcile net loss to net cash
   provided by (used in) operating activities:
      Depreciation  and  amortization                               6,096                       0
      Changes in operating assets and liabilities:
         Patent costs                                              (1,500)                      0
         State tax refund receivable                                  270                       0
         Trade accounts payable and accrued expenses              155,552                       0
                                                           ----------------             ----------
Net cash provided by (used in) operating activities              (128,356)                      0

INVESTING ACTIVITIES
Capital expenditures                                               (5,145)                      0
Reverse merger                                                   (150,000)                      0
Related parties                                                         0                       0
                                                           ----------------             ----------
Net cash provided by (used in) investing activities              (155,145)                      0

FINANCING ACTIVITIES
Principal payments on long-term debt                              (16,054)                      0
Proceeds from issuance of stock                                   421,860                       0
                                                           ----------------             ----------
Net cash provided by financing activities                         405,806                       0
                                                           ----------------             ----------
(DECREASE) INCREASE IN CASH                                       122,305                       0
Cash and cash equivalents at beginning of period                   24,135                       0
                                                           ----------------             ----------
Cash and cash equivalents at end of priod               $         146,440               $       0
                                                           ================             ==========


</TABLE>


See notes to financial statements.


<PAGE>


<TABLE>
<CAPTION>


PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF SHAREHOLDERS' EQUITY
For the Period August 5, 1996 (Inception) through March 31, 2000
(Unaudited)

                                                                                                                 Deficit
                                                                                                               Accumulated
                                                                                               Additional       During the
                                                                            Common              Paid in        Development
                                                                            Stock                Capital (3)      Stage       Total
                                                                --------------------------------------------------------------------
<S>                                                              <C>                <C>       <C>          <C>          <C>
Issuance of 4,000,000 shares - August 7, 1996                     4,000,000  (1)    $  4,000    $           $           $     4,000
Issuance of 77,320 shares - January 23, 1997                         77,320               77        9,923                    10,000
Issuance of 300,000 shares - January 23, 1997                       300,000  (2)         300                                    300
Issuance of 86,800 shares - Various dates in 1997                    86,800               87       35,118                    35,205
Issuance of 480,000 shares - Various dates in 1997
                                                                    480,000              480      254,520                   255,000
Net loss for the period August 5, 1996 (Inception) through
     July 31, 1997                                                                                            (325,680)    (325,680)
                                                                --------------------------------------------------------------------
Balance at July 31, 1997                                          4,944,120            4,944      299,561     (325,680)     (21,175)
Issuance of 970,193 shares - Various dates in 1998                  970,193              970      417,927                   418,897
Repurchase of 225,000 shares - Various dates in 1998               (225,000)            (225)     (99,775)                 (100,000)
Issuance of 129,500 shares - Various dates in 1998                  129,500              130       18,390                    18,520
Reduction of paid in capital for management fees                                                   (8,377)                   (8,377)
Net loss for the year ended July 31, 1998                                                                     (778,556)    (778,556)
                                                                --------------------------------------------------------------------
Balance at July 31, 1998                                          5,818,813            5,819      627,726   (1,104,236)    (470,691)
Issuance of 178,000 shares - Various dates in 1998                  178,000              178       72,372                    72,550
Repurchase of 73,000 shares - Various dates in 1998                 (73,000)             (73)      (5,227)                  (5,300)
Issuance of 43,000 shares - Various dates in 1998                    43,000               43       87,442                    87,485
Reduction of paid in capital for management fees                                                  (16,215)                  (16,215)
Net loss for 5 months ended December 31, 1998                                                                 (403,184)    (403,184)
                                                                --------------------------------------------------------------------
Balance at December 31, 1998                                      5,966,813            5,967      766,098   (1,507,420)    (735,355)
Issuance of 4,576,555 shares - Various dates in 1999              4,576,555            4,576      482,296                   486,872
Net loss for the year ended December 31, 1999                                                                 (862,998)    (862,998)
                                                                --------------------------------------------------------------------
Balance at December 31, 1999                                     10,543,368         $ 10,543  $ 1,248,394  $(2,370,418) $(1,111,481)
Issuance of 1,974,500 shares - Various dates in 1Q99              3,158,783            3,159      268,701                   271,860
Reverse merger - amount paid
Net loss 1Q2000                                                                                               (288,774)    (288,774)
                                                                --------------------------------------------------------------------
Balance at March 31, 2000                                        13,702,151           13,702    1,517,095   (2,659,192)  (1,128,395)
                                                                ====================================================================

</TABLE>


(1) See Note 5 to the financial statements.
(2)  Stock  issued  in  exchange  for legal  expenses,  administrative  fees and
commissions relating to the stock offering.
(3) Stock issue costs deducted from  additional  paid in capital  related to the
offering/sale totaled $53,697.


See notes to Financial Statements which are an integral part of this statement.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC
(A DEVELOPMENT STAGE COMPANY)
SCHEDULES OF GENERAL AND ADMINISTRATIVE EXPENSES
(Unaudited)




                                                  March 31, 2000
                                                 ----------------
Amortization expense                           $             559
Bank fees                                                  3,087
Commissions                                                    0
Donations                                                      0
Insurance                                                      0
Freight expense                                            1,216
Miscellaneous expense                                      2,741
Professional fees                                         35,480
Rent expense                                               8,279
Supplies                                                  22,080
Telephone                                                  3,810
Travel                                                    10,159
Utilities                                                  3,432
Outside lab expense                                        3,690
Payroll and benefits                                     179,405
Marketing                                                  1,553
Management fees                                            6,000
                                                 ----------------
                                               $         281,491
                                                 ================
 <PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 2000

Note 1 - Organization and Business Activity

Pathobiotek  Diagnostics,  Inc.  (the  "Company")  was formed on August 5, 1996,
under the laws of the State of Texas for the purpose of  developing,  producing,
distributing,  selling  and/or  performing  diagnostics  for  various  virus and
bacterium.  The Company is a  developmental  stage  company  under  Statement of
Financial  Accounting  Standard  ("SFAS") No. 7,  "Accounting  and  Reporting by
Development Stage Enterprises." Pathobiotek Diagnostics, Inc. is a subsidiary of
Pacific Biotech International, Inc. (the "Parent"), a Texas corporation.

Note 2 - Summary of Significant Accounting Policies

Cash and Cash Equivalents:  The Company considers all highly liquid  investments
with maturities of three months or less when purchased to be cash equivalents.

Supplemental schedule of non-cash investing and financing activities:
Equipment  totaling  $91,887  was  acquired  through  a note  payable  financing
agreement.

Property and Equipment: Property and equipment,  consisting primarily of lab and
computer  equipment,  is  stated at cost.  Depreciation  is  computed  using the
straight-line method over estimated lives ranging from 5 to 7 years.

Maintenance and repairs  are expensd as incurred; major renewals an improvements
are capitalized.

Use of  Estimates:  Management  uses  estimates  and  assumptions  in  preparing
financial  statements.  Those  estimates  and  assumptions  affect the  reported
amounts  of  assets  and  liabilities,  the  disclosure  contingent  assets  and
liabilities, and the reported revenues and expenses. Actual results could differ
from the estimates.

Concentration  of Credit Risk:  The  Company's  financial  instruments  that are
subject to concentrations of credit risk consist of cash. The Company places its
cash in a high credit quality  institution.  At some times, such balances may be
in excess of the FDIC insurance limits.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - Continued
March 31, 2000

Asset  Valuation:  The  carrying  amounts  of  long-lived  assets  are  reviewed
periodically.  If the asset  carrying  amount is not  recoverable,  the asset is
considered to be impaired and the value is adjusted.

Amortization  of Patent Related Costs: In connection with the issuance of shares
of stock to the Parent  (Note 5), the  company was  assigned  and  licensed  all
technological  applications of one U.S. Patent Application.  Legal costs related
to the  application  incurred by the Company are  capitalized in accordance with
management's estimation and expectation of securing a patent.

Capitalized patent related costs are amortized on a straight-line basis over the
expected life of the patent starting from the application date.

Income Taxes: The Company utilizes  Statement of Financial  Accounting  Standard
No.  109,  "Accounting  for Income  Taxes"  ("SFAS  109").  Under SFAS 109,  the
liability  method is used in  accounting  for income  taxes.  Under this method,
deferred tax assets and liabilities are determined based on differences  between
financial  reporting  and tax bases of assets and  liabilities  and are measured
using the enacted  statutory  tax rates and laws that will be in effect when the
differences reverse.

Fair Value of Financial Instruments:  The carrying amounts of cash, receivables,
and payables  approximate their fair values due to the short-term  maturities of
these instruments.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - Continued
March 31, 2000

Note 3 - Note Payable - Related Party

In  connection  with the purchase of lab  equipment and supplies from the Parent
totaling $91,887,  the company entered into a promissory note payable agreement.
The  remaining  balance of $71,236  and any unpaid  interest is due on or before
maturity of July 31, 2000. The note is secured by the lab equipment.

Note 4 - Income Taxes

The Company has incurred net operating losses of $2,659,192 since inception.  No
tax benefit has been recorded  relating to these losses  because  realization of
the carryforward benefit is uncertain.  For tax purposes, the net operating loss
carryforwards will expire beginning in the year 2012.

Note 5 - Related Party Transactions

On August 7, 1996, the Company issued  4,000,000  shares of stock to the Parent,
Pacific Biotech  International,  Inc. in exchange for certain  intangible assets
consisting  primarily  of license  rights  and  technological  applications.  In
accordance with APB 16 and 29, the exchange was recorded at the Parent company's
historical  capitalized  basis,  which was not considered  material at August 7,
1996.

In March 1999, the Company issued an additional 2,000,000 shares of stock to the
Parent in  exchange  for  certain  intangible  assets as  described  above.  The
exchange  was recorded at the Parent  company's  historical  capitalized  basis,
which was not considered material at March 1999. An additional  2,000,000 shares
is due to the Parent as of December  31,  1999.  This  exchange  will not have a
material affect on the Company's financial position.

Note 6 - Subscribed Stock

In additional to the 2,000,000 shares due to the parent company (Note 5) and the
2,673,125 shares due to executives of the company for compensation  (Note 8), at
March 31, 2000, there were 1,184,283 shares subscribed but not yet issued.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - Continued
March 31, 2000

Note 7 - Leases

The Company leases office space and certain  equipment under  operating  leases.
Future minimum lease payments are as follows:

                                        Year
                                       Ended
                                     December 31,
                                     ------------

                                        2000                    $9,266
                                        2001                       725
                                                                ------
                                                                $9,991
                                                                ======


Rent expense for the quarter ended March 31, 2000 was $8,279.
Rent expense from August 5, 1996 through March 31, 2000 was $105,752.

Note 8 - Stock-Based Compensation

Stock-based  compensation  plans are  accounted  for using the  intrinsic  value
method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees."  Under this method,  compensation cost is recognized
based on the fair value at the grant  dates for awards  under those  plans.  The
accompanying  financial statements include compensation costs of $82,031 for the
quarter ended March 31, 2000 and  $1,002,422  for the period from August 5, 1996
(Inception)  through March 31, 2000,  representing a total of 2,673,  125 shares
due for stock-based compensation.

<PAGE>


ITEM 2. MANAGEMENTS  DISCUSSION AND ANALYSIS OF FINANCIAL  CONDITION AND RESULTS
OF OPERATIONS

RESULTS OF  OPERATIONS  FOR THE QUARTER  ENDED  MARCH 31, 2000  COMPARED TO SAME
QUARTER IN 1999

The Company had  experienced  expenses for the three month period of $287,028 in
2000 and $0 in 1999. The difference in expenses for the years was as a result of
the merger of Pathobiotek Diagnostics,  Inc. and Investra Enterprises,  Inc. The
Company had no revenues for the period in 2000 or 1999.  The Company  recorded a
loss for the period in 2000 of $(287,028) for general and  administrative  costs
compared to $0 income/loss  in the same period 1999.  Loss per share was ($.012)
in the quarter in 2000.  The Company can expect losses until business and income
can be achieved.  While the Company is seeking  capital  sources for investment,
there is no assurance that sources can be found.

LIQUIDITY AND CAPITAL RESOURCES

The Company had minimal cash capital at the end of the period.  The Company will
be forced to either borrow or make private  placements of stock in order to fund
operations.  No  assurance  exists as to the  ability to  achieve  loans or make
private placements of stock.

<PAGE>

                           PART II - OTHER INFORMATION

ITEM 1.           LEGAL PROCEEDINGS

                  None

ITEM 2.           CHANGES IN SECURITIES

                    On March 6, 2000, Pathobiotek Diagnostics,  Inc. completed a
                    Share  Purchase  Agreement  with  shareholders  of  Investra
                    Enterprises,  Inc. in which  Pathobiotek  Diagnostics,  Inc.
                    acquired  all of the  issued and  outstanding  shares of the
                    Registrant  from  the  five  shareholders  for  purposes  of
                    completing  a Merger of  Pathobiotek  Diagnostics,  Inc. and
                    Investra  Enterprises,  Inc.  On March 6,  2000  Pathobiotek
                    Diagnostics, Inc. and Investra Enterprises, Inc. completed a
                    merger  with   Pathobiotek   Diagnostics,   Inc.  being  the
                    surviving entity.

ITEM 3.           DEFAULT UPON SENIOR SECURITIES

                  None.

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

                  None.

ITEM 5.           OTHER INFORMATION

                  None.

ITEM 6.           EXHIBITS AND REPORTS ON FORM 8-K

        A)  A report on Form 8-K was made on March 7, 2000 during the period for
            for which this report is filed.

        B)  A  report on Form 8-K was made on  April 14, 2000  during the period
            for which this report is filed.

<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Date: June 6, 2000



                                              PATHOBIOTEK DIAGNOSTICS, INC.


                                              /s/ Robert Simpson
                                              -----------------------------
                                              President